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Background: Metabolic Syndrome (MetS) is a high risk factor for Cardiovascular Diseases (CVD). We estimated to
investigate how MetS prevalence by glucose homeostasis varies across different age and gender groups.
Methods: We studied 9257 Chinese subjects over the age of 15 years in two cross-sectional surveys in 2006. With
oral glucose tolerance test (OGTT) test, 2341 subjects were normal glucose tolerance (NGT), and 5448 were
diagnosed as having type 2 diabetes (T2D). All other 1468 subjects were considered to be impaired fasting glucose
(IFG) or impaired glucose tolerance (IGT) subjects. Diabetes was diagnosis by WHO99 criteria. We used modified
NCEP-III criteria for the diagnosis of MetS.
Results: The prevalences of MetS in the male NGT, IFG/IGT and T2D groups were 25.9% (404/1559), 65.6% (769/
1172), and 73.5% (2483/3376), respectively. The prevalences of MetS in the female NGT, IFG/IGT and T2D groups
were 13.4% (105/782), 51.0% (151/296), and 75.4% (1563/2072), respectively. The prevalence of MetS in the male
IFG/IGT group gradually decreased from 73.26% to 41.08% in subjects over the age of 30 years. The prevalence of
MetS in the female IFG/IGT group gradually increased from 30% to 75% with aging.
Conclusions: The prevalence of MetS in subjects with different glucose tolerances in China was high and gradually
increased with impaired glucose homeostasis both in males and females.
Keywords: Metabolic syndrome, Diabetes, Impaired fasting glucose, Impaired glucose toleranceBackground
The current understanding of Metabolic Syndrome
(MetS) is based on a cluster of conditions: dysglycemia,
dyslipidemia, hypertension, and the procoagulant state
[1,2]. Accumulated data suggest that MetS is an immedi-
ate precursor to cardiovascular disease (CVD) [3]. More-
over, subjects with diabetes are known to be at greater
risk for CVD than subjects without diabetes [4]. The
prevalence of MetS in the world is rapidly increasing [4].
According to NCEP-ATPIII criteria [5], it is approxi-
mately 21.0% in Oman [6], 23.0% in Arab Americans [7],
38.8% in men and 22.2% in women in Finland [8], 34.5%* Correspondence: zhouzg@hotmail.com
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reproduction in any medium, provided the or[9] in adults but 5.2% in youth [10] in the US and from
9.8% to 46.5% in developing countries [11].
With the economic development of China, the preva-
lence of MetS has increased significantly. In 1992,
according to a national investigation, the prevalence of
MetS in mainland China was about 14.4% in men and
20% in women according to NCEP-ATPIII criteria [12].
In 2000–2001, another national survey showed that ap-
proximately 13.7% of adults aged 35–74 years had MetS
as defined by NCEP-ATP III criteria [13]. In 2008, the
prevalence of MetS in China increased to 23.3% accord-
ing to the modified NCEP-ATPIII criteria [14]. MetS has
become an important public health problem in China.
According to the latest national study, diabetes is
prevalent in China. The prevalences of MetS in T2D
subjects and IFG/IGT subjects now are worth to studytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[15]. To date, a study regarding MetS having a large
sample size with subjects of different glucose homeosta-
sis status has never been undertaken in China. There-
fore, we designed this study to investigate the prevalence
of MetS and its components in subjects of different glu-
cose homeostasis status with an unusual big sample size
(n = 9257), including those subjects with Normal Glu-
cose Tolerance (NGT), Impaired Fasting Glucose (IFG)/




This was a cross-sectional study and included subjects
from two large-sample investigations: the Railway Sys-
tem Staff Investigation and the LADA China multicenter
investigation. The Railway Staff investigation was carried
out in November and December of 2006. Subjects who
were 18–75 years old from the Railway System were
recruited for a diabetes screening. The inclusion criteria
for this study including: 1) age 18–75 years old male and
female; 2) willing to accept Oral Glucose Tolerance Test
(OGTT). The exclusion criteria for this study including:
1) malignancy; 2) pregnancy. The LADA China multi-
center investigation was initiated in June of 2006 and
finished in January of 2007 in 46 hospitals around China.
The inclusion criteria for this study including: 1) diagno-
sis of diabetes (WHO 99 criteria) at age ≥ 15.0 years,
2) disease duration of less than 1 year, 3) no ketoacidosis
in the first 6 months after the diagnosis of diabetes and
4) insulin independence (usage of insulin less than 1
month) for 6 months after diagnosis. Exclusion criteria
were 1) secondary diabetes, 2) diabetes in pregnancy and
gestational diabetes, and 3) malignancy. Subjects greater
than 15 years old and those newly diagnosed with T2D
were further screened for islet autoantibodies. Fasting
blood samples were drawn and screened for glucose.
Overall, 2341 subjects whose fasting plasma glucose
(FPG) was lower than 5.6 mmol/L were placed into the
normal glucose tolerance (NGT) group. Subjects with an
FPG between 5.6 mmol/L and 7.0 mmol/L were given
an oral glucose tolerance test (OGTT). In total, 5448
subjects with an FPG greater than 7.0 mmol/L or post-
prandial plasma glucose (PPG) greater than 11.1 mmol/L
were diagnosed with T2D. All other subjects (1468 sub-
jects) were considered as impaired fasting glucose (IFG)
or impaired glucose tolerance (IGT) subjects. MetS was
diagnosed according to the modified National Choles-
terol Education Program Third Adult Treatment Panel
(NCEP-ATPIII) criteria [5].
The Ethics Review Committee/Institutional Review
Board of the Second Xiangya Hospital of Central South
University approved the study protocol. The study wasconducted in accordance with the Declaration of Helsinki.
All participants provided written informed consent.
Sample collection and diagnosis criteria
After collecting a detailed history, including duration of
diabetes, past medical history, family history, and medi-
cation history, fasting blood samples were collected from
each subject.
Basic characteristics were collected by well trained
clinical physician in each center, including age, height
(Ht), weight (Wt), body mass index (BMI), waist circum-
ference (WC), hip circumference (HC), waist to hip ratio
(WHR), systolic blood pressure (SBP), and diastolic
blood pressure (DBP). We required all venous blood
samples to be tested immediately for fasting glucose
level and lipids. Triglycerides (TG), total cholesterol
(TC), high-density lipid cholesterol (HDL-Ch), low-
density lipid cholesterol (LDL-Ch) and fasting plasma
glucose (FPG) were recorded for each patient.
Obesity (BMI ≥ 30 kg/m2) and overweight (BMI ≥ 25
kg/m2) were defined by WHO 97 criteria [16]. Hyper-
tension was defined as SBP ≥ 140 mmHg or DBP ≥ 90
mmHg or current use of antihypertensive medications
(by WHO-ISH 99 criteria) [17]. Abnormal blood pres-
sure, central obesity, abnormal TG and abnormal HDL-
ch were defined according to the modified NCEP-ATPIII
criteria. MetS was diagnosed with the modified NCEP-
ATPIII criteria [5].
Statistical analysis
Statistical analysis was performed with SPSS statistical
software (version 13; SPSS, Chicago, IL). Normally dis-
tributed data were expressed as the means ± SD. Vari-
ables with a skewed distribution were reported as
median (range). Logarithmic transformations were ap-
plied to non-normally distributed parameters. Frequency
differences were compared using the χ2 test or Fisher’s
exact test when appropriate. Variance analysis was used
for comparisons of means between groups by the inde-
pendent t test, the t’ test or one-way ANOVA when ap-
propriate. The nonparametric Wilcoxon test was used
for parameters that were not normally distributed after
transformation. Pairware comparison was used by the
one-way ANOVA Post Hoc test. OR was calculated by
complex samples logistic regression methods. P values
less than 0.05 were considered statistically significant.
Results
Basic characteristics of subjects
In total, there were 6107 male subjects, including 1559
NGT, 1172 IFG/IGT, and 3376 T2D subjects, and 3150
female subjects, including 782NGT, 296 IFG/IGT and
2072 T2D subjects. We compared basic clinical charac-
teristics among the subjects (Table 1). In males, BMI,
Table 1 Clinical characteristics of the NGT, IFG/IGT and T2D subjects
Male Female
NGT IFG/IGT T2D P value NGT IFG/ T T2D P value
(N = 1559) (N = 1172) (N = 3376) (N = 782) (N = 96) (N = 2072)
Age (yrs) 47.09 ± 8.47 49.89 ± 6.66*** 52.54 ± 12.07***### <0.001 43.18 ± 8.65 46.80 ± 6 4*** 48.90 ± 12.07***### <0.001
Ht (cm) 168.22 ± 7.19 168.22 ± 7.59 169.81 ± 6.89***### <0.001 158.04 ± 7.75 158.53 ± 5 9 157.80 ± 5.54 0.133
Wt (kg) 67.32 ± 9.76 71.30 ± 9.53*** 72.33 ± 11.50***## <0.001 56.33 ± 8.19 59.71 ± 8 6*** 60.81 ± 9.97*** <0.001
BMI (kg/m2) 23.74 ± 2.92 25.12 ± 2.86*** 25.01 ± 3.35*** <0.001 22.50 ± 3.08 23.74 ± 3 9*** 24.39 ± 3.59***## <0.001
WC (cm) 83.47 ± 8.70 87.56 ± 8.23*** 89.87 ± 9.81***### <0.001 75.48 ± 7.67 78.92 ± 8 3*** 84.47 ± 9.70***### <0.001
HC (cm) 95.61 ± 6.30 97.72 ± 6.48*** 97.25 ± 8.56*** <0.001 93.06 ± 5.92 95.15 ± 6 3*** 95.17 ± 8.91*** <0.001
WHR 0.8717 ± 0.05382 0.8943 ± 0.05194*** 0.9251 ± 0.06421***### <0.001 0.8103 ± 0.05402 0.8287 ± 0 5390*** 0.8877 ± 0.07221***### <0.001
SBP (mmHg) 119.21 ± 17.52 127.18 ± 18.46*** 126.55 ± 16.99*** <0.001 113.37 ± 17.27 121.29 ± 2 .35*** 128.64 ± 19.12***### <0.001
DBP (mmHg) 78.78 ± 11.43 83.35 ± 11.10*** 81.06 ± 10.45***### <0.001 73.42 ± 11.60 77.72 ± 1 .88*** 79.56 ± 10.51***## <0.001
TG (mmol/L) 1.50(0.30-28.86) 1.78(0.42-28.26)** 1.87(.06-34.15)***### <0.001 1.06(0.26-29.31) 1.32(0.36 3.14)** 1.65(0.24-22.69)***## <0.001
TC (mmol/L) 5.12(2.37–11.45) 5.34(2.64–14.42)*** 4.93(.04–42.20)***### <0.001 5.05(2.19–10.37) 5.22(3.40 7.74)** 4.93(1.03-15.85)### 0.002
HDL-ch (mmol/L) 1.25(0.36–3.82) 1.21(0.41–2.65)* 1.10(0.09–7.58)** 0.007 1.42(0.65–2.52) 1.35(0.54 2.23)* 1.26(0.04-11.11)* 0.019
LDL-ch (mmol/L) 3.16(0.94–8.39) 3.32(1.16–10.82)*** 2.82(0.12–12.67)***### <0.001 3.12(0.53–7.50) 3.30(1.79 5.35)** 2.78(0.40-13.50)***### <0.001
FBS (mmol/L) 5.23(3.84–5.59) 5.90(4.57–6.99)*** 7.80(3.84–22.81)***### <0.001 5.16(3.90–5.59) 5.82(4.76 6.90)*** 8.43(2.68-16.00)***### <0.001
Compared with NGT *P<0.05, **P<0.01, ***P<0.001;


































Table 2 Prevalence of the MetS in different gender group
Overall Male Female
NGT IFG/IGT T2D N T IFG/IGT T2D NGT IFG/IGT T2D
N 2341 1468 5448 1559 1172 3376 782 296 2072
MetS 509 920 4046 404 769 2483 105 151 1563
95%CI 21.7% 62.7% 74.3% 25.9% 65.6%*** 73.6%***### 13.4%&&& 51.0%***&&& 75.4%***###
(20.1–23.4) (60.2–65.2) (73.1–75.4) (23.7–28.1) (62.9–68.3) (72.1–75.0) (11.03–15.82 (45.3-56.8) (73.6-77.3)
OR Ref 6.078 10.435 Ref 5.486 7.956 Ref 6.752 20.018
(5.261–7.020) (9.297–11.711) (4.650–6.472) (6.940–9.120) (4.971-9.172) (15.928-25.157)
Compared with NGT *P<0.05, **P<0.01, ***P<0.001;
Compared with IFG/IGT #P<0.05, ##P<0.01, ###P<0.001;



















Table 3 Age-related prevalence of the MetS in subjects with different gender
Male Female
NGT IFG/IGT T2D P value for trends NGT IFG/IGT T2D P value for trends
N 1559 1172 3376 782 296 2072
<30 18.1%(15/83) 35.7%(5/14) 63.9%(115/180)***# P<0.001 3.3%(3/91)## 30.0%(3/10)* 54.9%(39/71)*** P < 0.001
%95CI (9.6–26.5) (7.0–64.4) (56.8–71.0) (−0.4–7.0) (−4.6–64.6) (43.1-66.8)
OR Ref 2.519(0.738–8.591) 8.021(4.244–15.157) Ref 12.571(2.129–74.233) 35.750(10.324-123.791)
30-39 20.0%(42/210) 73.3%(63/86)*** 75.1%(410/546)*** P<0.001 3.8%(4/106)&&& 34.8%(8/23)***&& 61.2%(137/224)&&& P < 0.001
%95CI (14.6–25.5) (63.7–82.8) (71.5–78.7) (0.09–7.5) (13.7–55.8) (54.7-67.6)
OR Ref 10.957(6.103–19.669) 12.059(8.166–17.807) Ref 13.600(3.644–50.754) 40.155(14.271-112.986)
40-49 26.1%(130/499) 69.1%(237/343)*** 74.2%(783/1055)*** P<0.001 15.7%(69/441)&&& 52.0%(93/179)***&&& 67.8%(328/484)***###& P < 0.001
%95CI (22.2–29.9) (64.2–74.1) (71.6–76.9) (12.2–19.1) (44.6–59.4) (63.6-72.0)
OR Ref 6.346(4.683–8.601) 8.171(6.409–10.417) Ref 5.830(3.948–8.610) 11.336(8.232-15.609)
50-59 28.0%(210/750) 64.2%(457/712)*** 74.1%(754/1018)***### P<0.001 19.7%(28/142)& 55.0%(44/80)*** 79.9%(563/705)***###&& P < 0.001
%95CI (24.8–31.2) (60.7–67.8) (71.4–76.8) (13.1-26.3) (43.9-66.1) (76.9-82.8)
OR Ref 4.608(3.694-5.749) 7.344(5.940-9.081) Ref 4.976(2.720-9.104) 16.142(10.267-25.380)
≥60 41.2% (7/17) 41.2%(7/17) 73.0%(421/577)**## P<0.001 50.0%(1/2) 75.0%(3/4) 84.4%(496/588)&&& P = 0.364
%95CI (15.1–67.3) (15.1–67.3) (69.3–76.6) (−5.9–6.9) (−4.6–154.6) (81.4-87.3)
OR Ref 1.000(0.255-3.919) 3.855(1.442-10.305) Ref 3.000(0.084-107.447) 5.391(0.334-86.965)
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http://www.biomedcentral.com/1471-2458/12/675SBP and HDL-Ch were similar between the IFG/IGT
and T2D subjects. All other indexes increased or
decreased gradually from the NGT to the IFG/IGT to
the T2D groups (P<0.001 for all comparisons). In
females, Ht was similar among the NGT, IFG/IGT and
T2D groups. Wt, HC and HDL-Ch were similar between
the IFG/IGT and T2D groups but lower in the NGT
group. Other clinical characteristics increased or
decreased gradually from the NGT to the IFG/IGT to
the T2D groups (P<0.05 for all comparisons).
The prevalences of MetS in different gender subgroups
The overall prevalences of MetS in the NGT, IFG/IGT
and T2D groups were 21.7% (20.1–23.4), 62.7% (60.2–
65.2), and 74.3% (73.1–75.4), respectively. Considering
gender differences, as shown in Table 2, The prevalences
of MetS in the male NGT, IFG/IGT and T2D groups
were 25.9% (23.7–28.1), 65.6% (62.9–68.3), and 73.5%
(72.1–75.0), respectively. The prevalences of MetS in the
female NGT, IFG/IGT and T2D groups were 13.4%
(11.03–15.82), 51.0% (45.3–56.8), and 75.4% (73.6–77.3),
respectively.
The prevalences of MetS in different age subgroups
We stratified the population by age (Table 3). For the
male NGT group, the <20-year-old subjects had the low-
est prevalence of MetS compared with the other age
groups.
In the male NGT group, the prevalence of MetS grad-
ually increased with aging, from 20.0% (31–40 yrs old)
to 41.18% (> 61 yrs old). In the male T2D group, the
MetS prevalence stayed at a very high level (more than
70%) after age 30. In the IFG/IGT group, the prevalence
of MetS in the male IFG/IGT group gradually decreased
from 73.26% (31–40 yrs old) to 41.18% (> 61 yrs old).
Notably, in the 31-to-40-year-old male IFG/IGT group,
the prevalence of MetS increased greatly when com-
pared with the less-than-20-year-old group [73.26% (63/
86) vs. 35.71% (5/14), P<0.001]. The prevalence of MetS
in the female NGT, IFG/IGT and T2D groups all showed
increasing trends with age. Notably, the OR of MetS in
31-to-40-year-old male subjects was 10.957 (6.103–
19.669) in the IFG/IGT group and 12.059 (8.166–17.807)
in the T2D group when compared with the NGT group.
In female 31-to-40-year-old subjects, the OR was 13.600
(3.644–50.754) in the IFG/IGT group and, surprisingly,
40.155 (14.271–112.986) in the T2D group when com-
pared with the NGT group.
Metabolic component disorder among the subgroups
We studied whether the presence of glucose abnormal-
ities is associated with the number of positive MetS as
well. In both male and female subgroups, it is obviously
that the number of metabolic disorders was increasingwith the worsen glucose level from NGT, IFG/IGT to
T2D subgroups. A correlation analysis also found that
both in male and female group, the presence of MetS is
associated continuously with FPG levels in both male
and female group (P<0.001 for both).
We compared the abnormal metabolic components of
MetS among the subgroups in Table 4. In male subjects,
the abnormal blood pressure (IFG/IGT vs. T2D: 57.3%
vs. 55.6%, P>0.05) did not increase with worsening glu-
cose homeostasis between the IFG/IGT and T2D sub-
jects, although both of them were higher than the NGT
group (P<0.001 for all). However, in females, the preva-
lences of abnormal blood pressure and hypertension
were increased from the NGT group to the IFG/IGT
group to the T2D group, which was in accordance with
the glucose homeostasis changes (P<0.001 for all).
WC-diagnosed central obesity gradually increased from
the NGT group to the IFG/IGT group to the T2D group
in both the male and female subjects. However, BMI-
defined overweight and obesity in the male IFG/IGT
group was similar to the male T2D group (51.1% vs.
47.8%, P>0.05), although both of them were higher than
the NGT group (32.9%, P<0.001 for both). In females, the
prevalence of overweight and obesity gradually increased
with worsening glucose homeostasis (P<0.001 for all).
For lipid profiles, the prevalence of abnormal TG in
the male IFG/IGT group was similar to that in the T2D
group (57.1% vs. 59.5%, P>0.05) but higher than that in
the NGT group (43.1%, P<0.001 for all). The prevalence
of abnormal HDL-Ch in both males and females was
increased with worsening glucose homeostasis (P<0.001
for all).
Discussion
Our study showed that MetS was prevalent not only in
NGT subjects but also in IFG/IGT and T2D subjects. In
this Chinese study population, the overall prevalence of
MetS in the IFG/IGT group (62.73%) was between that
of the NGT group (21.68%) and the T2D group
(74.29%). In the Stop-NIDDM study, the prevalence of
MetS was about 61% in the IFG/IGT population [18]. A
study in Finland that used WHO criteria to diagnose
MetS found that in women and men, respectively, the
metabolic syndrome was seen in 10% and 15% of sub-
jects with NGT, 42% and 64% of subjects with IFG/IGT,
and 78% and 84% of subjects with T2D [19]. In the Dia-
betes in Germany (DIG) study, the prevalence of MetS
in T2D subjects was as high as 74.4% [20]. Overall, our
data are similar to those from studies of Caucasian sub-
jects. Strikingly, compared with NGT subjects, the OR of
MetS in T2D subjects is very high in both men and
women. The data suggest that when glucose homeostasis
is damaged, other metabolic components become worse,
and the prevalence of MetS increases.
Table 4 Metabolic disorders in different gender subjects
Male Female
NGT IFG/IGT T2D P value for trends NGT IFG/IGT T2D P value for trends
N 1559 1172 3376 782 296 2072
Abnormal Blood Pressure 556 (35.6%) 672 (57.3%)*** 1879 (55.5%)*** <0.001 169 (21.4%)&&& 112 (37.8%)***&&& 1165 (56.2%)***### <0.001
95%CI (33.2–38.0) (54.5–60.2) (53.9–57.2) (18.5–24.2) (32.3–43.4) (53.8-58.1)
Odds Ratio Ref 2.420(2.072–2.826) 2.255(1.993–2.552) Ref 2.198(1.646–2.937) 4.648(3.840-5.626)
Hypertension 382 (24.5%) 506 (43.2%)*** 1345 (39.8%)***# <0.001 108 (13.8%)&&& 77 (26.0%)***&&& 915 (44.0%)***###&& <0.001
95%CI (22.3–26.6) (40.3–46.0) (38.1–41.4) (11.4–16.2) (21.0–31.0) (41.8-46.1)
Odds Ratio Ref 2.334(1.983–2.748) 2.035(1.779–2.328) Ref 2.187(1.573–3.041) 4.931(3.954-6.149)
Central obesity 392 (25.1%) 497 (42.2%)*** 1716 (50.8%)***### <0.001 248 (31.6%)&& 129 (43.2%)*** 1459 (70.4%)***###&&& <0.001
95%CI (22.9–27.2) (39.4–45.1) (49.1–52.5) (28.3–34.9) (37.6–48.9) (68.2-72.2)
Odds Ratio Ref 2.186(1.858–2.572) 3.066(2.685–3.501) Ref 1.656(1.259–2.178) 5.097(4.269-6.086)
Overweight & Obesity 513 (32.9%) 599 (51.1%)*** 1614 (47.8%)*** <0.001 149 (19.1%)&&& 77 (26.0%)**&&& 835 (40.3%)***###&&& <0.001
95%CI (31.0–35.0) (48.0–54.0) (46.0–49.0) (16.0–22.0) (21.0–31.0) (38.0-42.0)
Odds Ratio Ref 2.124(1.818–2.482) 1.862(1.643–2.110) Ref 1.490(1.087–2.041) 2.867(2.350-3.498)
Abnormal Triglycerides 672 (43.1%) 669 (57.1%)*** 2010 (59.5%)*** <0.001 144 (18.4%)&&& 111 (37.5%)***&&& 1079 (52.1%)***###&&& <0.001
95%CI (40.6–45.5) (54.0–59.7) (57.7–61.1) (15.7–21.1) (32.0–43.1) (49.5-53.8)
Odds Ratio Ref 1.749(1.501–2.038) 1.934(1.713–2.184) Ref 2.646(1.968–3.559) 4.806(3.934-5.871)
Abnormal HDL cholesterol 718 (46.1%) 687 (58.6%)*** 2349 (69.6%)***### <0.001 286 (36.6%)&&& 157 (53.0%)*** 1455 (70.2%)***### <0.001
(43.5–48.5) (55.5–61.2) (67.9–71.0) (33.8–40.6) (48–59.4) (68.7-72.7)
Odds Ratio Ref 1.653(1.419–1.926) 2.662(2.353–3.012) Ref 1.947(1.486–2.550) 4.070(3.424-4.838)
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http://www.biomedcentral.com/1471-2458/12/675Many studies have shown that in different glucose
homeostasis subgroups, the prevalence of MetS can
predict CVD [20-22]. In a study carried out in Finland,
cardiovascular heart disease history was related to MetS
in all three subgroups: NGT, IFG/IGT, and T2D. How-
ever, previous Myocardial Infarction (MI) history was
found to be significant only in the IFG/IGT group, and
previous stroke was found to be significant in the T2D
group [19]. Due to the high prevalences of MetS in
IFG/IGT and T2D Chinese subjects, CVD and other
vascular diseases, such as stroke, should be paid atten-
tion to, and this would be a heavy burden for both in-
dividual families and the public medical service system
in China. However, to be note, debates and doubts
about the predictive ability of MetS for adverse cardio
and cerebrovascular events currently exist as well. Since
our data is from cross-sectional data, readers should be
cautious too.
Surprisingly, we found that in the IFG/IGT group,
the prevalence of MetS gradually decreased in males
greater than 30 years of age. However, in the female
IFG/IGT group, the opposite trend was present. This
phenomenon is the same as that previously reported
for the frequency of obesity in IFG/IGT subjects [13].
We believe that this may be because more and more
IFG/IGT subjects would develop T2D in old age if they
already had MetS during young age. Second, because
the present analyses are based on cross-sectional data,
the increasing prevalence of MetS in the younger age
groups could be due, in some degree, to a cohort ef-
fect. The lower prevalence of MetS in IFG/IGT subjects
of greater than 61 years of age might also be due to a
survivor effect, for example, if people who had MetS
were more likely to die before that age and were not
available for study [13]. Third, we cannot exclude that
the higher prevalence noted in the younger age groups
might represent an overall increase in the prevalence of
MetS in recent years because of lifestyle changes in
China [15]. The 31-to-40-year-old age group of IFG/
IGT and T2D subjects (either male or female) had the
highest OR of MetS compared with the NGT group.
This finding suggests that comprehensive intervention
for MetS should occur as early as 30 or before 30 years
of age.
Gender differences were found in our study. Accord-
ing to the modified NCEP-ATPIII criteria, the preva-
lences of MetS in the NGT and IFG/IGT groups were
higher in males than in females. Our data are different
from a previous report in China that showed that preva-
lence of MetS was higher in women than in men (17.8%
vs. 9.8%) according to 2001 ATPIII criteria [12,13]. Al-
though most investigations in Caucasians have not
found gender differences [23,24], many other reports
have had results similar to our own [9,25]. We believethat different diagnostic criteria affect the prevalence of
MetS in different genders. The IDF criteria use central
obesity as its central diagnostic criterion. Based on our
data and data from other studies [13], females in China
have a higher prevalence of central obesity than males.
The IDF criteria and the modified NCEP-ATPIII criteria
have already changed the diagnostic criteria for central
obesity and HDL-Ch according to different ethnic popu-
lations. Previous reports have shown that after chan-
ging the diagnostic criteria, which were modified for
ethnic differences, the prevalence of MetS increased
approximately 10% in Chinese males but decreased 2%
in Chinese females [13]. After considering the change in
diagnostic criteria, sex hormones should be considered to
explain the differences in MetS between males and
females. One study has found that higher testosterone and
sex hormone binding globulin (SHBG) levels in aging
males are associated with higher insulin sensitivity and a
reduced risk for MetS independently of insulin levels and
body composition measurements [26]. Another study has
found that low testosterone and SHBG levels are strongly
associated not only with components of MetS but also
with MetS itself independent of BMI. Furthermore, sex
hormones are associated with inflammation and body iron
stores. Even in the absence of late-stage consequences,
such as diabetes and cardiovascular disease, subtle
derangements in sex hormones are present in the meta-
bolic syndrome and may contribute to its pathogenesis
[27]. Another interesting finding is that for different meta-
bolic disorders, or MetS component in male subjects,
quite often, including abnormal blood pressure, over-
weight and abnormal TG levels had a similar frequency in
both IFG/IGT and T2D groups. This suggested in male,
some of the MetS components worsen as early as in IFG/
IGT group.
Although until now this study is the biggest to investi-
gate MetS in different glucose homeostasis subjects in
China, we acknowledge some limitations in this study.
Most of the subjects lived in urban areas, and the T2D
subjects were mostly from clinics and hospitals. This
study was only a cross-sectional study, which cannot
predict the risk of CVD directly. To be note, due to lim-
ited group size, especially the IFG subjects in female
group, we didn’t separate the IFG and IGT subjects.
Thus, further longitude follow up study with a even big
sample size of IFG and IGT subjects should be carried
out. Some inflammatory cytokines such as hs-CRP,
which has been proved closely related to MetS and CVD
could be measured as well.
Conclusions
Our large sample multicenter cross-sectional investiga-
tion showed that the prevalence of MetS in Chinese
was increased from NGT, IFG/IGT to T2D subjects.
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